Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.
Term
Q3 2026
“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”
Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
For the nine months ended September 30, 2026, Acrivon Therapeutics reported a net loss of $54.9 million, a slight improvement from the $58.9 million loss in the prior year period. The company's cash position decreased to $47.5 million from $41.5 million at year-end 2025, while short-term investments dropped significantly from $77.1 million to $30.2 million.
Acrivon Therapeutics hosted a corporate R&D event and webcast featuring Key Opinion Leaders to introduce its new immunology and inflammation (I&I) programs, ACR-525 and a PKCθ inhibitor. The company filed a formal investor presentation deck detailing the preclinical programs and development plans for Eosinophilic esophagitis (EoE) identified via its AP3 platform.